Apolipoprotein E Christchurch - Heparan sulfate proteoglycan interface (APOEch-HSPG interface)

The Apolipoprotein E Christchurch - Heparan sulfate proteoglycan (HSPG) interface is a critical molecular interaction site involved in the pathogenesis of Alzheimer's disease (Arboleda-Velasquez et al., 2019) [1]. The 'Christchurch' mutation (R154S) occurs in the heparin-binding domain of APOE and was first identified in a patient who showed remarkable resistance to early-onset Alzheimer's despite carrying a high-risk genetic background (Chen et al., 2024) [2]. This mutation significantly reduces the binding affinity of APOE to cell-surface HSPGs, which are known to facilitate the internalization of pathological tau seeds (Zhao et al., 2023) [3]. By disrupting this interface, the spread of neurofibrillary tangles is slowed, providing a potent neuroprotective effect. Current therapeutic research focuses on developing monoclonal antibodies, such as 7C11, or small molecules that can mimic this effect by blocking the APOE-HSPG interaction (Marino et al., 2023) [4]. This target represents a shift in Alzheimer's drug development toward enhancing endogenous protective mechanisms and preventing tau-mediated neurodegeneration.

Other names

APOE3ch-HSPG interfaceAPOE R154S-HSPG interactionAPOE2-Christchurch interfaceApolipoprotein E Christchurch variant binding site

Inhibition of the interaction between Apolipoprotein E and Heparan sulfate proteoglycans to prevent the cellular uptake and propagation of tau aggregates.